Eden's GLP-1 program pairs a low headline price with a required membership, and the two combine into a very different monthly figure. This independent review walks through what the program includes, how the pricing really stacks up, and the genetic factor Eden does not measure.

An independent editorial look at Brello Health's weight-loss program: who it serves, how the telehealth consultation and pharmacy model work, the medication menu, cost ranges, and the genetic context most GLP-1 programs never capture.

An independent editorial review of Brello and tirzepatide: what makes this GIP/GLP-1 dual agonist different, how branded and compounded prescriptions are routed, what the SURMOUNT trials showed, cost factors, and the genetics behind tirzepatide's pathways.

An independent editorial look at Brello's GLP-1 program: the medications a telehealth-plus-compounding model can dispense, how you get from intake to a first fill, and what the fee covers. Plus the pathway-level genetics most programs never examine before prescribing.

This independent editorial review breaks down the Ro weight-loss program: the intake and prescription flow, GLP-1 medication options, and the factors that shape monthly cost. It also explains the pathway-level genetic context Ro and most telehealth programs do not measure.

Ro's GLP-1 program runs on a subscription telehealth model. This independent editorial overview walks through how evaluation, prescription, and dispensing work, what the subscription covers, and the upstream genetic context Ro's model does not include before a compound is prescribed.

This independent editorial review breaks down Noom's GLP-1 medication add-on: how the app-plus-prescription model handles evaluation and dispensing, what the offering typically costs each month, the trial evidence behind GLP-1 drugs, and where pathway-level genetic context fits into a metabolic decision the app itself never measures.

An independent program-level editorial review of the Hims weight loss offering: who it is built for, the GLP-1 medication options, how provider oversight and the pharmacy pathway work, what a member pays, and the genetic starting point the program never measures.

The Hers weight-management program combines medication options with a telehealth service model. This independent editorial review explains how the approach works, which medications it can involve, the provider and pharmacy structure, and the genetic groundwork any protocol rests on.

Strut Health review: oral semaglutide lozenges $99-$149/mo, injectable $189-$289/mo, FDA warning letter Feb 2026, D+ BBB rating, cancellation friction. Compared to PlexusDx Microdose GLP-1 ($129/mo), Semaglutide Injection ($189/mo), and Tirzepatide Injection ($289/mo) with the optional Precision Peptide Genetic Test for dose personalization.

Henry charges $297/month month-to-month for injectable compounded semaglutide with consultation and shipping included — comprehensive but mid-to-upper tier; its tirzepatide is an oral dissolving tablet only, sold as a 3-month supply. We compare Henry's annualized cost ($3,564/year) against PlexusDx Weight Management Protocols ($1,548–$3,468/year), explain the compounded vs FDA-approved branded medication question, and walk through dose flexibility and genetic baseline differences so you can pick the right cash-pay GLP-1 route.

DudeMeds advertises compounded semaglutide and tirzepatide from $149+/month with no membership fee, but dose-escalation pricing is not consistently published and review depth is still thin. This review compares DudeMeds against PlexusDx Weight Management Protocols (Microdose GLP-1 at $129/mo flat, Semaglutide Injection $189/mo, Tirzepatide Injection $289/mo) and the optional Precision Peptide Genetic Test for genetic-informed titration.

Sprout Health offers compounded semaglutide at $249/mo and compounded tirzepatide at $299/mo across 44 states with documented slow customer service. Compare Sprout's pricing, state coverage, FDA-approval status, and clinical model with PlexusDx Weight Management Protocols ($129/mo to $349/mo, all 50 states, optional Precision Peptide Genetic Test).

Honest review of Willow GLP-1 patient reviews, pricing ($299-$549/mo), compounded sourcing, and how PlexusDx Weight Management Protocols compare on cost, formulary, state availability, and the optional Precision Peptide Genetic Test for individualized dose decisions.

Synergy Rx GLP-1 review: real maintenance pricing, compounded vs branded medication source, cash-pay alternatives, and how PlexusDx Weight Management Protocols compare on price, delivery format, and genetic baseline.

An honest, verified review of Skinny Rx tirzepatide tablets — the $299/month buccal-dissolve compounded product, the February 2026 FDA warning letter, and the actual evidence picture for any oral tirzepatide formulation — with a feature-by-feature comparison to PlexusDx Tirzepatide Oral Protocol ($349/mo, 5mg to 25mg daily across seven dose levels) as the cash-pay alternative.

MEDVi sells two different oral GLP-1 products under one banner: a compounded semaglutide tablet priced after the intake questionnaire and a Wegovy pill route on a separate membership plus medication. We unpack the pricing, the FDA regulatory status, the 72-hour cancellation rule, and where PlexusDx Semaglutide Oral ($289/mo+) and Microdose GLP-1 Protocol ($129/mo flat) fit for cash-pay readers who want a non-injection GLP-1.

Is SHED legit? Yes — verified LLC, named pharmacy partners, 875+ reviews — but with a 2-month minimum and 72-hour cancellation cutoff. Compare SHED to PlexusDx Weight Management Protocols: month-to-month, no membership, with optional Precision Peptide Genetic Test before titration.

Eden semaglutide reviews split between a 4.4/5 Trustpilot score and BBB billing complaints. We verify Eden's real cost — $99/mo advertised, $198/mo all-in with the required membership (July 2026) — against PlexusDx Semaglutide Injection ($189/mo) and Microdose GLP-1 ($129/mo flat).

A plain-language look at semaglutide weight loss injections: how the GLP-1 receptor mechanism curbs appetite, what the SUSTAIN, STEP, and PIONEER programs reported, which label warnings matter most, and how your genetic pathway profile fits into an informed provider conversation.

Tirzepatide is a GIP and GLP-1 dual receptor agonist studied for weight loss in the SURPASS and SURMOUNT programs. This overview explains the mechanism, the reported evidence range, the contraindications worth knowing, and the genetic variables upstream of every GLP-1 decision.

Ozempic Before and After explained — what is being described, why it can happen, what the published trial evidence shows, and the GLP-1 pathway genetic context. Treated with clinical dignity. Individual results vary.

Ozempic (semaglutide) is searched heavily for weight loss though its own approval is for type 2 diabetes. This article covers the GLP-1 mechanism, what the SUSTAIN trial literature reports, label authority, contraindications, and the genetic layer beneath the pathway, as of April 2026.

A biology-first look at Rybelsus for weight loss: how oral semaglutide acts on appetite and satiety, what the PIONEER program reported, how the FDA label frames its use, key contraindications, and where pathway-level genetics informs the weight-loss conversation you have with a qualified healthcare provider.

Semaglutide is widely searched for weight loss. This page explains the GLP-1 mechanism, the clinical trial evidence and reported weight range, the FDA approvals and labeling, the contraindications worth knowing, and the inherited genetic variable that shapes every GLP-1 decision.

Zepbound (tirzepatide, Eli Lilly) is a GLP-1 receptor agonist with a well-characterized safety profile. This article covers common side effects, serious warnings, the boxed-warning context, and when to call a provider — plus the genetic variables that shape baseline GLP-1 biology.

Rybelsus is oral semaglutide, and this independent explainer covers what the tablet is, the GLP-1 receptor biology it uses, what the PIONEER program measured, how its FDA diabetes label frames weight change, and the inherited variants that shape any GLP-1 pathway decision.

A GLP-1 receptor agonist is widely searched in a weight-loss context. This guide covers how it works at the pathway level, what the published trials show, the FDA labeling context as of April 2026, the limitations worth knowing, and the genetics upstream of every decision.

GLP-1 receptor agonists are widely searched for weight loss as a category. This guide covers the shared mechanism, what the major trial programs reported, the FDA labeling context as of April 2026, the limitations worth knowing, and the genetics upstream of every decision.